NEW YORK--(BUSINESS WIRE)--
Roy Jacobs & Associates a law firm representing investors nationwide, is
investigating potential claims on behalf of shareholders of STAAR
Surgical Co. (“STAAR” or the “Company”) (NASDAQ:STAA) concerning
possible breaches of fiduciary duty and securities law violations.
For further information, please contact Roy L. Jacobs, Esq. toll-free at
1-888-884-4490 or by e-mail at email@example.com.
STAAR Surgical Company, together with its subsidiaries, designs,
develops, manufactures, and sells implantable lenses for the eye, and
delivery systems to deliver lenses into the eye. The investigation is
focused on potential breaches of fiduciary duty on the part of the STAAR
Board of Directors involving the failure to maintain good manufacturing
practices for its products.
On June 30, 2014, the U.S. Food and Drug Administration publicly
released a Warning Letter, dated May 21, 2014, concerning an inspection
of STAAR's Monrovia Facility which took place from February 10, 2014 to
March 21, 2014, stating that there were several regulatory violations at
the facility. The Warning Letter noted inadequacies with the
manufacture, packing, storage and installation of the Company's
implantable lenses and inadequate procedures for documentation,
complaints, sterility testing, and record maintenance. The Warning
Letter also threatened regulatory action. On this news, the price of
STAAR's shares plummeted by over 11%
If you held STAAR shares since prior to April 10, 2014 and continue to
hold your shares; and you are interested in discussing your rights or
have information relating to this investigation, please contact Roy L.
Jacobs. Mr. Jacobs will be glad to personally speak with you at no cost
ROY JACOBS & ASSOCIATES
Roy L. Jacobs, Esq., 1-888-884-4490
Source: Roy Jacobs & Associates